Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · see citing works

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · see citing works

<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229 · see citing works

Cetuximab for the Treatment of Colorectal Cancer

Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904 · see citing works

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

Cartron, G., Dacheux, L., Salles, G., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,902 · see citing works

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694 · see citing works

KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Lièvre, A., Bachet, J., Boige, V., Cayre, A., Corre, D. L., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,456 · see citing works

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · see citing works

Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125 · see citing works

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081 · see citing works

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ <i>neu</i> –Positive Metastatic Breast Cancer

Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · see citing works

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941 · see citing works

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausová, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 940 · see citing works

Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies

Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830 · see citing works

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827 · see citing works

FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

Koene, H. R., Kleijer, M., Algra, J., Roos, D., Borne, A. E. G. K. V. D., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 796 · see citing works

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734 · see citing works

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Arnould, L., Gelly-Marty, M., Penault-Llorca, F. M., Benoît, L., Bonnetain, F., Migeon, C., Cabaret, V., Fermeaux, V., Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 545 · see citing works

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

Frattini, M., Saletti, P., Romagnani, E., Martin, V, Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L. L., Cavalli, F., & Mazzucchelli, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604009 · Cited by 540 · see citing works

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Lenz, H., Cutsem, E. V., Khambata‐Ford, S., Mayer, R. J., Gold, P. J., Stella, P. J., Mirtsching, B. C., Cohn, A. L., Pippas, A. W., Azarnia, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7595 · Cited by 522 · see citing works

FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab

Zhang, W., Gordon, M. A., Schultheis, A. M., Yang, D., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482 · see citing works

Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines

Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435 · see citing works

On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.

Parren, P. W. H. I., Warmerdam, P. A. M., Boeije, L. C. M., Arts, J. A. J., WESTERDAAL, N. A. C., Vlug, A., Capel, P. J., Aarden, L. A., & van de Winkel, J. G. J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116022 · Cited by 346 · see citing works

Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: Contribution of FCGR2B to genetic susceptibility

Kyogoku, C., Dijstelbloem, H. M., Tsuchiya, N., Hatta, Y., Kato, H., Yamaguchi, A., Fukazawa, T., Jansen, M., Hashimoto, H., van de Winkel, J. G. J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10257 · Cited by 333 · see citing works

Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

Cutsem, E. V., Nowacki, M. P., Láng, I., Cascinu, S., Shchepotin, I. B., Maurel, J., Rougier, P. R., Cunningham, D., Nippgen, J., & Köhne, C.-H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4000 · Cited by 313 · see citing works

FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy

van Sorge, N. M., van der Pol, W.-L., & van de Winkel, J. G. J. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00037.x · Cited by 293 · see citing works

Molecular determinants of cetuximab efficacy.

Vallböhmer, D., Zhang, W., Gordon, M., Yang, D. Y., Yun, J., Press, O. A., Rhodes, K. E., Sherrod, A. E., Iqbal, S., Danenberg, K. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.100 · Cited by 234 · see citing works

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

Farag, S. S., Flinn, I. W., Modali, R., Lehman, T. A., Young, D. C., & Byrd, J. C. (2003) · Blood · doi:10.1182/blood-2003-07-2548 · Cited by 208 · see citing works

Cetuximab induce antibody‐dependent cellular cytotoxicity against EGFR‐expressing esophageal squamous cell carcinoma

Kawaguchi, Y., Kono, K., Mimura, K., Sugai, H., Akaike, H., & Fujii, H. (2006) · International Journal of Cancer · doi:10.1002/ijc.22370 · Cited by 174 · see citing works

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

Personeni, N., Fieuws, S., Piessevaux, H. H., Hertogh, G. D., Schutter, J. D., Biesmans, B., Roock, W. D., Capoen, A., Dêbiec‐Rychter, M., Laethem, J. V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0449 · Cited by 173 · see citing works

A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects

Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 129 · see citing works

Structural motifs involved in human IgG antibody effector functions

Greenwood, J., Clark, M., & Waldmann, H. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230518 · Cited by 126 · see citing works

Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy

Scartozzi, M., Bearzi, I., Pierantoni, C., Mandolesi, A., Loupakis, F., Zaniboni, A., Catalano, V., Quadri, A., Zorzi, F., Berardi, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5022 · Cited by 125 · see citing works

Monoclonal antibody mechanisms of action in cancer

Weiner, G. J. (2007) · Immunologic Research · doi:10.1007/s12026-007-0073-4 · Cited by 122 · see citing works

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

Lin, T. S., Flinn, I. W., Modali, R., Lehman, T. A., Webb, J. L., Waymer, S., Moran, M. E., Lucas, M. S., Farag, S. S., & Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-02-0651 · Cited by 80 · see citing works

Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR

Dall’Ozzo, S., Andres, C. R., BARDOS, P., Watier, H., & Thibault, G. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00123-6 · Cited by 60 · see citing works

2008 Gastrointestinal Cancers Symposium

Fricker, J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70054-8 · Cited by 46 · see citing works

Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer

Spano, J., Milano, G. A., Vignot, S., & Khayat, D. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.11.005 · Cited by 43 · see citing works

Correlation Between the Response to Cetuximab Alone or in Combination With Irinotecan and the Activated/Phosphorylated Epidermal Growth Factor Receptor in Metastatic Colorectal Cancer

Personeni, N., Hendlisz, A., Gallez, J., Galdón, M. G., Larsimont, D., VANLAETHEM, J., NAGY, N., Barette, M., Paesmans, M., & Cardoso, F. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.04.029 · Cited by 30 · see citing works

T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?

Raynaud, P., Caulet-Maugendre, S., Foussard, C., Salles, G., Moreau, A., Rossi, J. F., Patey, M., Béné, M. C., Béné, M. C., Damotte, D., et al. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.05.026 · Cited by 26 · see citing works

Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy

Sako, T., Burioka, N., Yasuda, K., Tomita, K., Miyata, M., Kurai, J., Chikumi, H., Watanabe, M., Suyama, H., Fukuoka, Y., et al. (2004) · Acta Oncologica · doi:10.1080/02841860310016226 · Cited by 23 · see citing works

High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab

Kang, X., Patel, D., Ng, S. K., Melchior, M., Ludwig, D. L., & J, D. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3041 · Cited by 22 · see citing works

Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma

Pennell, N., Bhanji, T., Zhang, L., Seth, A. K., Sawka, C. A., & Berinstein, N. L. (2008) · Haematologica · doi:10.3324/haematol.12638 · Cited by 11 · see citing works

Antibody therapy of cancer

Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3236 · Cited by 2,167 · see citing works

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · see citing works

Macrophages as tools and targets in cancer therapy

Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807 · see citing works

Monoclonal antibodies: versatile platforms for cancer immunotherapy

Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,282 · see citing works

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C. A., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 983 · see citing works

Monoclonal Antibodies in Cancer Therapy

Zahavi, D. J., & Weiner, L. M. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 845 · see citing works

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

Thierry, A. R., Mouliere, F. C., Messaoudi, S. E., Mollévi, C., Lopez‐Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 681 · see citing works

The secret ally: immunostimulation by anticancer drugs

Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670 · see citing works

NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 573 · see citing works

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

Siena, S., Bianchi, A. S., Nicolantonio, F. D., Balfour, J., & Bardelli, A. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 526 · see citing works

Type I and type II Fc receptors regulate innate and adaptive immunity

Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B. M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 504 · see citing works

Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

Maubec, E., Petrow, P. K., Scheer-Senyarich, I., Duvillard, P., Lacroix, L., Gelly, J., Certain, A., Duval, X., Crickx, B., Buffard, V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1735 · Cited by 469 · see citing works

Targeting the ERBB family in cancer: couples therapy

Tebbutt, N. C., Pedersen, M. W., & Johns, T. G. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3559 · Cited by 464 · see citing works

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436 · see citing works

Immunotherapy of cancer in 2012

Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H. M., Kaliński, P., & Ferrone, S. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436 · see citing works

Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins

Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428 · see citing works

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 417 · see citing works

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells

Klingemann, H., Boissel, L., & Toneguzzo, F. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00091 · Cited by 414 · see citing works

Fc glycans of therapeutic antibodies as critical quality attributes

Reusch, D., & Tejada, M. L. (2015) · Glycobiology · doi:10.1093/glycob/cwv065 · Cited by 406 · see citing works

IgG Fc engineering to modulate antibody effector functions

Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein &amp; Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356 · see citing works

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

Hogarth, P. M., & Pietersz, G. A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2909 · Cited by 348 · see citing works

Advancement and applications of peptide phage display technology in biomedical science

Wu, C., Liu, I.-J., Lu, R., & Wu, H. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0223-x · Cited by 343 · see citing works

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6360 · Cited by 320 · see citing works

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients

Srivastava, R. M., Lee, S. C., Filho, P. A. A., Lord, C. A., Jie, H.-B., Davidson, H. C., López‐Albaitero, A., Gibson, S. P., Gooding, W. E., Ferrone, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2426 · Cited by 321 · see citing works

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

Janne, P. A., Gray, N. S., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303 · see citing works

The immune system and response to HER2-targeted treatment in breast cancer

Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 282 · see citing works

Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

Loo, D. T., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S. N., Burke, S., Ciccarone, V. C., Li, H., Yang, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0715 · Cited by 282 · see citing works

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Kohrt, H. E. K., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuséri, N., Bonnafous, C., Czerwinski, D. K., Rajapaksa, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519199 · Cited by 282 · see citing works

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

Apétoh, L., Ladoire, S., Coukos, G., & Ghiringhelli, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv209 · Cited by 281 · see citing works

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Huang, Z., Blum, R. H., Bjordahl, R., Gaidarova, S., Rogers, P., Lee, T. T., Abujarour, R., Bonello, G. B., Wu, J., Tsai, P.-F., et al. (2019) · Blood · doi:10.1182/blood.2019000621 · Cited by 278 · see citing works

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten Hagen, T. L. M., Kubes, P., & van Egmond, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66776 · Cited by 276 · see citing works

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

Nordstrom, J. L., Gorlatov, S. N., Zhang, W., Yang, Y., Huang, L., Burke, S., Li, H., Ciccarone, V. C., Zhāng, T., Stavenhagen, J. B., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3069 · Cited by 249 · see citing works

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S. A., Lawrence, D. A., Li, Y., Pitti, R. M., Tótpál, K., Yee, S. F., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 247 · see citing works

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · see citing works

Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies

Seidel, U. J. E., Schlegel, P., & Lang, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00076 · Cited by 236 · see citing works

KRAS mutation testing in metastatic colorectal cancer.

Tan, C., & Du, X. (2012) · PubMed Central · doi:10.3748/wjg.v18.i37.5171 · Cited by 230 · see citing works

Signaling by Antibodies: Recent Progress

Bournazos, S., Wang, T. T., Dahan, R., Maamary, J., & Ravetch, J. V. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052433 · Cited by 230 · see citing works

CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes

Yeap, W. H., Wong, K. L., Shimasaki, N., Teo, E. C. Y., Quek, J. K. S., Yong, H. X., Diong, C. P., Bertoletti, A., Linn, Y. C., & Wong, S. C. (2016) · Scientific Reports · doi:10.1038/srep34310 · Cited by 230 · see citing works

Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

White, A. L., Chan, H. T. C., Roghanian, A., French, R. R., Mockridge, C. I., Tutt, A. L., Dixon, S. V., Ajona, D., Verbeek, J. S., Al‐Shamkhani, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101135 · Cited by 227 · see citing works

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

Schneider‐Merck, T., van Bueren, J. J. L., Berger, S., Rossen, K., van Berkel, P. H. C., Derer, S., Beyer, T. D., Lohse, S., Bleeker, W. K., Peipp, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900847 · Cited by 223 · see citing works

Tumor-associated myeloid cells: diversity and therapeutic targeting

Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C., & Allavena, P. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00613-4 · Cited by 218 · see citing works

Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications

Levy, E. M., Roberti, M. P., & Mordoh, J. (2011) · BioMed Research International · doi:10.1155/2011/676198 · Cited by 218 · see citing works

Anti–Tumor Necrosis Factor-α Antibodies Induce Regulatory Macrophages in an Fc Region-Dependent Manner

Vos, A. C. W., Wildenberg, M. E., Duijvestein, M., Verhaar, A. P., BRINK, G. R. V. D., & Hommes, D. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.10.008 · Cited by 218 · see citing works

Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer

Gül, N., & van Egmond, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1330 · Cited by 212 · see citing works

Tricking the balance: NK cells in anti-cancer immunity

Pahl, J. H. W., & Cerwenka, A. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.07.012 · Cited by 204 · see citing works

T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing

Kudo, K., Imai, C., Lorenzini, P. A., Kamiya, T., Kono, K., Davidoff, A. M., Chng, W. J., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1365 · Cited by 187 · see citing works

Fcγ Receptor Function and the Design of Vaccination Strategies

Bournazos, S., & Ravetch, J. V. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.009 · Cited by 187 · see citing works

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

Tamura, K., Shimizu, C., Hojo, T., Akashi‐Tanaka, S., Kinoshita, T., Yonemori, K., Kouno, T., Katsumata, N., Ando, M., Aogi, K., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq585 · Cited by 186 · see citing works

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele

Jochéms, C., Hodge, J. W., Fantini, M. C., Fujii, R., Morillon, Y. M., Greiner, J. W., Padget, M. R., Tritsch, S. R., Tsang, K. Y., Campbell, K. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13411 · Cited by 182 · see citing works

Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies

Thomann, M., Reckermann, K., Reusch, D., Prasser, J., & Tejada, M. L. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.03.002 · Cited by 179 · see citing works

Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review

Tol, J., & Punt, C. J. A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.012 · Cited by 175 · see citing works

Monoclonal antibodies for the treatment of cancer

Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 172 · see citing works

Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer

Dahabreh, I. J., Terasawa, T., Castaldi, P. J., & Trikalinos, T. A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00006 · Cited by 169 · see citing works

Use of Allogeneic NK Cells for Cancer Immunotherapy

Geller, M. A., & Miller, J. S. (2011) · Immunotherapy · doi:10.2217/imt.11.131 · Cited by 163 · see citing works

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy

Almagro, J. C., Daniels‐Wells, T. R., Pérez‐Tapia, S. M., & Penichet, M. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01751 · Cited by 158 · see citing works

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

Cheung, N. V., Guo, H.-F., Hu, J., Tassev, D. V., & Cheung, I. Y. (2012) · OncoImmunology · doi:10.4161/onci.19864 · Cited by 153 · see citing works

Cleavage of IgGs by proteases associated with invasive diseases

Brezski, R. J., & Jordan, R. E. (2010) · mAbs · doi:10.4161/mabs.2.3.11780 · Cited by 154 · see citing works

Genomics and emerging biomarkers for immunotherapy of colorectal cancer

Kather, J. N., Halama, N., & Jaeger, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.010 · Cited by 150 · see citing works

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies

Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 152 · see citing works

Fcγ receptor pathways during active and passive immunization

Bournazos, S., & Ravetch, J. V. (2015) · Immunological Reviews · doi:10.1111/imr.12343 · Cited by 147 · see citing works

The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease

Anania, J. C., Chenoweth, A. M., Wines, B. D., & Hogarth, P. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00464 · Cited by 146 · see citing works

iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting

Goldenson, B. H., Hor, P., & Kaufman, D. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841107 · Cited by 147 · see citing works

Boosting therapeutic potency of antibodies by taming Fc domain functions

Kang, T. H., & Jung, S. T. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0345-9 · Cited by 142 · see citing works

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance

Krumbach, R., Schüler, J. B., Hofmann, M., Giesemann, T., Fiebig, H., & Beckers, T. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.12.019 · Cited by 141 · see citing works

CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells

Pahl, J. H. W., Koch, J., Götz, J.-J., Arnold, A., Reusch, U., Gantke, T., Rajkovic, E., Treder, M., & Cerwenka, A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0550 · Cited by 137 · see citing works

89Zr-cetuximab PET imaging in patients with advanced colorectal cancer

van Oordt, C. W. M. D. H., Gootjes, E. C., Huisman, M. C., Vugts, D. J., Roth, C., Luik, A. M., Mulder, E. R., Schuit, R. C., Boellaard, R., Hoekstra, O. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4672 · Cited by 136 · see citing works

SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline

Guéguinou, M., Harnois, T., Crottès, D., Uguen, A., Déliot, N., Gambade, A., Chantôme, A., Haelters, J. P., Jaffrès, P. A., Jourdan, M. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8786 · Cited by 135 · see citing works

Therapeutic monoclonal antibody N-glycosylation – Structure, function and therapeutic potential

Cymer, F., Beck, H., Rohde, A., & Reusch, D. (2017) · Biologicals · doi:10.1016/j.biologicals.2017.11.001 · Cited by 136 · see citing works

A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

Zhang, W., Winder, T., Ning, Y., Pohl, A. C., Yang, D., Kahn, M. R., Lurje, G., LaBonte, M. J., Wilson, P. M., Gordon, M. A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq315 · Cited by 137 · see citing works

Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients

Trivedi, S., Srivastava, R. M., Concha‐Benavente, F., Ferrone, S., García-Bates, T. M., Li, J., & Ferris, R. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2971 · Cited by 133 · see citing works

Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions

DiLillo, D. J., & Ravetch, J. V. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0120 · Cited by 132 · see citing works

Neutrophils as effector cells for antibody-based immunotherapy of cancer

van Egmond, M., & Bakema, J. E. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.12.002 · Cited by 132 · see citing works

Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy

Zahavi, D. J., Aldeghaither, D. S., O’Connell, A., & Weiner, L. M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby002 · Cited by 128 · see citing works

Complement in monoclonal antibody therapy of cancer

Rogers, L. M., Veeramani, S., & Weiner, G. J. (2014) · Immunologic Research · doi:10.1007/s12026-014-8542-z · Cited by 128 · see citing works

Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck

Sharafinski, M. E., Ferris, R. L., Ferrone, S., & Grandis, J. R. (2010) · Head & Neck · doi:10.1002/hed.21365 · Cited by 127 · see citing works

EGFR and KRAS in Colorectal Cancer

Markman, B., Ramos, F. J., Capdevila, J., & Tabernero, J. M. (2010) · Advances in clinical chemistry · doi:10.1016/s0065-2423(10)51004-7 · Cited by 126 · see citing works

Antibody Glycosylation and Inflammation

Shade, K.-T., & Anthony, R. M. (2013) · Antibodies · doi:10.3390/antib2030392 · Cited by 120 · see citing works

Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma

Cranmer, L. D., Engelhardt, C., & Morgan, S. S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0210 · Cited by 121 · see citing works

GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab

Gerdes, C. A., Nicolini, V., Herter, S., van Puijenbroek, E., Lang, S., Roemmele, M., Moessner, E., Freytag, O., Friess, T., Ries, C. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0989 · Cited by 118 · see citing works

IgA EGFR antibodies mediate tumour killing in vivo

Boross, P., Lohse, S., Nederend, M., Jansen, J. H. M., van Tetering, G., Dechant, M., Peipp, M., Royle, L., Liew, L. P., Boon, L., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201929 · Cited by 118 · see citing works

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients

Hurvitz, S. A., Betting, D. J., Stern, H. M., Quinaux, E., Stinson, J., Seshagiri, S., Zhao, Y., Buyse, M., Mackey, J., Driga, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2294 · Cited by 115 · see citing works

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer

Gavin, P. G., Song, N., Kim, S. R., Lipchik, C., Johnson, N. L., Bandos, H., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4884 · Cited by 113 · see citing works

Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function

Grugan, K. D., McCabe, F. L., Kinder, M., Greenplate, A. R., Harman, B. C., Ekert, J. E., van Rooijen, N., Anderson, G. M., Nemeth, J. A., Strohl, W. R., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201889 · Cited by 111 · see citing works

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia

Ågerstam, H., Karlsson, C., Hansen, N., Sandén, C., Askmyr, M., von Palffy, S., Högberg, C., Rissler, M., Wunderlich, M., Juliusson, G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422749112 · Cited by 111 · see citing works

Single-cell genomic approaches for developing the next generation of immunotherapies

Yofe, I., Dahan, R., & Amit, I. (2020) · Nature Medicine · doi:10.1038/s41591-019-0736-4 · Cited by 106 · see citing works

Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma

Pahl, J. H. W., Ruslan, S. E. N., Buddingh, E. P., Santos, S. J., Szuhai, K., Serra, M., Gelderblom, H. A. J., Hogendoorn, P. C. W., Egeler, R. M., Schilham, M. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2277 · Cited by 108 · see citing works

Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

Azzopardi, N., Lecomte, T., Ternant, D., Boisdron-Celle, M., Piller, F., Morel, A., Gouilleux‐Gruart, V., Desvignes, C., Watier, H., Gamelin, E. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1081 · Cited by 106 · see citing works

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy

Leconet, W., Larbouret, C., Chardès, T., Thomas, G., Neiveyans, M., Busson, M., Jarlier, M., Radosevic‐Robin, N., Pugnière, M., Bernex, F., et al. (2013) · Oncogene · doi:10.1038/onc.2013.487 · Cited by 107 · see citing works

Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands

Romano, S., Fonseca, N. A., Simões, S., Gonçalves, J., & Moreira, J. N. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.018 · Cited by 104 · see citing works

Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Manceau, G., Imbeaud, S., Thiébaut, R., Liébaert, F., Fontaine, K., Rousseau, F., Génin, B., Corre, D. L., Didelot, A., Vincent, M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2750 · Cited by 103 · see citing works

RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation

Mirschberger, C., Schiller, C., Schräml, M., Dimoudis, N., Friess, T., Gerdes, C. A., Reiff, U., Lifke, V., Hoelzlwimmer, G., Kolm, I., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0099 · Cited by 103 · see citing works

Taming the dragon: genomic biomarkers to individualize the treatment of cancer

Majewski, I. J., & Bernards, R. (2011) · Nature Medicine · doi:10.1038/nm.2311 · Cited by 99 · see citing works

Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab

Pander, J., Heusinkveld, M., van der Straaten, T., Jordanova, E. S., Baak-Pablo, R., Gelderblom, H., Morreau, H., van der Burg, S. H., Guchelaar, H.-J., & van Hall, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0239 · Cited by 101 · see citing works

Fcγ receptors: genetic variation, function, and disease

Hargreaves, C. E., Rose-Zerilli, M. J. J., Machado, L. R., Iriyama, C., Hollox, E. J., Cragg, M. S., & Strefford, J. C. (2015) · Immunological Reviews · doi:10.1111/imr.12341 · Cited by 102 · see citing works

Combination Strategies to Enhance Antitumor ADCC

Kohrt, H. E. K., Houot, R., Marabelle, A., Cho, H. J., Osman, K., Goldstein, M. J., Levy, R., & Brody, J. (2012) · Immunotherapy · doi:10.2217/imt.12.38 · Cited by 97 · see citing works

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines

Park, J., Kim, S.-E., Keam, B., Park, H.-R., Kim, S., Kim, M., Kim, T. M., Doh, J., Kim, D., & Heo, D. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000873 · Cited by 97 · see citing works

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations

Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 96 · see citing works

Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine

Nagelkerke, S. Q., Schmidt, D. E., de Haas, M., & Kuijpers, T. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02237 · Cited by 94 · see citing works

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells

Dixon, K. J., Wu, J., & Walcheck, B. K. (2021) · Cancers · doi:10.3390/cancers13020312 · Cited by 94 · see citing works

Association of FcγRIIa and FcγRIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan

Bibeau, F., Crapez, E., Fiore, F. D., Thézenas, S., Sabourin, J., Lamy, A., Frébourg, T., Michel, P., Ychou, M., & Boissière‐Michot, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11004 · Cited by 23 · see citing works

Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

Park, S., Hong, Y. S., Lee, J., Ryu, M., Chang, H. M., Kim, K., Ahn, Y., Na, Y.-S., Jin, D., Yu, C. S., et al. (2012) · Oncology · doi:10.1159/000335959 · Cited by 25 · see citing works

Role of polymorphic fc gamma receptor II/III in the efficacy of cetuximab in KRAS-NRAS-BRAF-PI3K mutated.

García‐Foncillas, J., Rodriguez, J., Boni, V., Sola, I., Honorato, B., Zárate, R., & Bandrés, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.477

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

Rodríguez, J., Zárate, R., Bandrés, E., Boni, V., Hernandez, A. B., Sola, J. J., Honorato, B., Bitarte, N., & García‐Foncillas, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.007 · Cited by 82 · see citing works

Fc gamma receptor polymorphisms and KRAS status as predictive biomarkers in patients with metastatic colorectal cancer treated with biweekly cetuximab-based salvage therapy.

Zárate, R., Bandrés, E., Rodriguez, J., Bitarte, N., Honorato, B., Boni, V., Sola, I., Ponz‐Sarvisé, M., Garzón, C., & García‐Foncillas, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13523